You may have forgotten — or wanted to forget — what happened on the internet in 2022. Here are some reminders.
Category: Food and Drug Administration
-
Vaping Settlement by Juul Is Said to Total $1.7 Billion
The proposed deal would resolve thousands of lawsuits in multidistrict litigation based in Northern California.
-
Lasik Patients Should Be Warned of Complications, FDA Draft Says
Draft recommendations by the agency describe dry eyes, visual disturbances and other side effects of the procedure. Surgeons say the benefits are being ignored.
-
Juul Agrees to Settle Thousands of Vaping Lawsuits
The deal is the latest in the company’s efforts to resolve litigation over its marketing of products that some contend fueled the teenage vaping crisis.
-
FDA Report Faults Agency’s Food Unit for Leaderless Dysfunction
Spurred by the infant formula crisis, a panel found that the agency shied away from tough decisions, sometimes fearing confrontations with industry over enforcement of critical public health issues.
-
FDA Considering New Approach to Blood Donation by Gay and Bisexual Men
The agency may put in place a personalized risk assessment to replace the current prohibition on men who have had sex with men in the previous three months.
-
Hemp-Fed Cows Get Buzzed, Study Finds, but Will Humans Who Drink Their Milk?
Hemp with high THC content given to Holsteins leached into their milk, according to a group of German scientists exploring the food chain for dairy production.
-
RJ Reynolds Sues California Over Flavored Tobacco Ban
On Tuesday, the state’s voters overwhelmingly supported letting a two-year-old law take effect. The company’s lawsuit is viewed by anti-smoking advocates as a tactic that could keep menthol cigarettes on the market longer.
-
Big Tobacco Heralds a Healthier World While Fighting Its Arrival
The industry continues to back smoking protections, like this November’s ballot initiative in California that would overturn a law banning tobacco flavors.
-
FDA Panel Recommends Pulling Preterm Birth Drug From the Market
The agency has weighed years of study that showed the treatment given accelerated approval 11 years ago was not effective.
-
F.D.A. Confirms Widespread Shortages of Adderall
The agency cited Teva’s continuing supply problems as well as those of other drug makers struggling to fill the gap.